PMC 3564852
Chronic stress elevates cortisol and inflammatory markers that worsen cardiovascular risk
Research published in The New England Journal of Medicine and replicated across multiple clinical trials consistently shows that weight loss from GLP-1 therapies follows a predictable curve: rapid early loss followed by a plateau, typically between weeks 12 and 24, before additional loss resumes or stabilizes
GLP1-S improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
After years of failure (and one controversial approval), there are now several anti-amyloid drugs available that can modestly slow Alzheimers progression
Here's a deep dive into its standout features and benefits: Access to GLP-1 Medications: Brello Health offers safe, supervised access to leading GLP-1 medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), which have been clinically proven to facilitate significant weight loss and enhance metabolic health